NextCure Inc. (NXTC)
2.23
0.00 (0.00%)
Upcoming Events
Latest Headlines
NXTC makes replay available for event on cancer drug trial data
June 4, 2026 8:01 AM - StreetInsider
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
June 4, 2026 8:00 AM - StreetInsider
Form 8-K NextCure, Inc. For: Jun 01
June 1, 2026 8:11 AM - SEC Filing
NextCure reports positive SIM0505 trial data for gynecologic cancers
June 1, 2026 8:01 AM - StreetInsider
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
June 1, 2026 8:00 AM - StreetInsider
Form SCHEDULE 13G/A NextCure, Inc. Filed by: SILVERARC CAPITAL MANAGEMENT, LLC
May 13, 2026 4:42 PM - SEC Filing
Lucid Capital Markets Starts NextCure Inc. (NXTC) at Buy
May 11, 2026 7:10 AM - StreetInsider
NextCure Inc. (NXTC) Misses Q1 EPS by 187c
May 8, 2026 5:42 AM - StreetInsider
Form 10-Q NextCure, Inc. For: Mar 31
May 7, 2026 4:30 PM - SEC Filing
Form 8-K NextCure, Inc. For: May 07
May 7, 2026 4:22 PM - SEC Filing
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
May 7, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G/A NextCure, Inc. Filed by: Simcere Zaiming, Inc.
May 6, 2026 9:27 PM - SEC Filing
NextCure begins dose optimization study for ovarian cancer drug
May 4, 2026 7:05 AM - StreetInsider
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
May 4, 2026 7:05 AM - Globe NewsWire
Form DEFA14A NextCure, Inc.
April 24, 2026 4:19 PM - SEC Filing
Form DEF 14A NextCure, Inc. For: Jun 18
April 24, 2026 4:16 PM - SEC Filing
NextCure to present SIM0505 cancer drug data at ASCO 2026
April 21, 2026 10:15 AM - StreetInsider
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
April 21, 2026 10:15 AM - StreetInsider
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
April 7, 2026 12:45 PM - Globe NewsWire
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
April 7, 2026 8:15 AM - StreetInsider
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
March 31, 2026 4:05 PM - StreetInsider
Full Article List